Etiology of the Protein-Energy Wasting Syndrome in Chronic Kidney Disease: A Consensus Statement From the International Society of Renal Nutrition and Metabolism (ISRNM)

Journal of Renal Nutrition

Volumn 23, Issue 2, 2013, Pages 77-90

  Carrero, Juan Jesús ^a   Stenvinkel, Peter ^a   Cuppari, Lilian ^b   Ikizler, T Alp ^c   Kalantar Zadeh, Kamyar ^d   Kaysen, George ^e   Mitch, William E ^f   Price, S Russ ^g,h   Wanner, Christoph ⁱ   Wang, Angela Y M ^j   Ter Wee, Pieter ^k   Franch, Harold A ^g,h  

^a KAROLINSKA INSTITUTE   (Sweden)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h ATLANTA VA MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF WÜRZBURG   (Germany)

^j UNIVERSITY OF HONG KONG   (Hong Kong)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE;

ABDOMINAL OBESITY; BLOOD; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONSENSUS; ENERGY METABOLISM; HUMAN; INFLAMMATION; LIFESTYLE; MOTOR ACTIVITY; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN CALORIE MALNUTRITION; RENAL REPLACEMENT THERAPY; REVIEW; WASTING SYNDROME;

ADIPOKINES; COMORBIDITY; CONSENSUS; ENERGY METABOLISM; HUMANS; INFLAMMATION; LIFE STYLE; MOTOR ACTIVITY; NUTRITIONAL STATUS; OBESITY, ABDOMINAL; PREVALENCE; PROTEIN-ENERGY MALNUTRITION; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; WASTING SYNDROME;

EID: 84874244749     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2013.01.001     Document Type: Review

References (205)

1. Fouque D., Kalantar-Zadeh K., Kopple J., Cano N., Chauveau P., Cuppari L., et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008, 73:391-398.
2. Hoffer L.J. The need for consistent criteria for identifying malnutrition. Nestle Nutr Workshop Ser Clin Perform Programme 2009, 12:41-52.
3. Araujo I.C., Kamimura M.A., Draibe S.A., Canziani M.E., Manfredi S.R., Avesani C.M., et al. Nutritional parameters and mortality in incident hemodialysis patients. J Ren Nutr 2006, 16:27-35.
4. Kalantar-Zadeh K., Supasyndh O., Lehn R.S., McAllister C.J., Kopple J.D. Normalized protein nitrogen appearance is correlated with hospitalization and mortality in hemodialysis patients with kt/v greater than 1.20. J Ren Nutr 2003, 13:15-25.
5. Bossola M., Muscaritoli M., Tazza L., Panocchia N., Liberatori M., Giungi S., et al. Variables associated with reduced dietary intake in hemodialysis patients. J Ren Nutr 2005, 15:244-252.
6. Burrowes J.D., Larive B., Chertow G.M., Cockram D.B., Dwyer J.T., Greene T., et al. Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the hemodialysis (HEMO) study. Nephrol Dial Transpl 2005, 20:2765-2774.
7. Bazanelli A.P., Kamimura M.A., da Silva C.B., Avesani C.M., Lopes M.G., Manfredi S.R., et al. Resting energy expenditure in peritoneal dialysis patients. Perit Dial Int 2006, 26:697-704.
8. Wang A.Y., Sea M.M., Ng K., Kwan M., Lui S.F., Woo J. Nutrient intake during peritoneal dialysis at the Prince of Wales Hospital in Hong Kong. Am J Kidney Dis 2007, 49:682-692.
9. Kloppenburg W.D., de Jong P.E., Huisman R.M. The contradiction of stable body mass despite low reported dietary energy intake in chronic haemodialysis patients. Nephrol Dial Transpl 2002, 17:1628-1633.
10. Bazanelli A.P., Kamimura M.A., Vasselai P., Draibe S.A., Cuppari L. Underreporting of energy intake in peritoneal dialysis patients. J Ren Nutr 2010, 20:263-269.
11. Huang X., Sjogren P., Cederholm T., Arnlov J., Lindholm B., Riserus U., et al. Serum and adipose tissue fatty acid composition as biomarkers of habitual dietary fat intake in elderly men with chronic kidney disease. Nephrol Dial Transpl 2012, Available at:, Accessed January 29, 2013. http://ndt.oxfordjournals.org/content/early/2012/12/09/ndt.gfs478.long.
12. Huang X., Stenvinkel P., Qureshi A.R., Cederholm T., Barany P., Heimburger O., et al. Clinical determinants and mortality predictability of stearoyl-coa desaturase-1 activity indices in dialysis patients. J Intern Med 2012 Aug 17, [Epub ahead of print]. 10.1111/j.1365-2796.2012.02573.x.
13. Huang X., Stenvinkel P., Qureshi A.R., Riserus U., Cederholm T., Barany P., et al. Essential polyunsaturated fatty acids, inflammation and mortality in dialysis patients. Nephrol Dial Transpl 2012, 27:3615-3620.
14. Jankowska M., Marszall M., Debska-Slizien A., Carrero J.J., Lindholm B., Czarnowski W., et al. Vitamin B6 and the immunity in kidney transplant recipients. J Ren Nutr 2013, 23:57-64.
15. Kalantar-Zadeh K., Kopple J.D., Deepak S., Block D., Block G. Food intake characteristics of hemodialysis patients as obtained by food frequency questionnaire. J Ren Nutr 2002, 12:17-31.
16. Krishnamurthy V.M., Wei G., Baird B.C., Murtaugh M., Chonchol M.B., Raphael K.L., et al. High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int 2012, 81:300-306.
17. Hollingdale R., Sutton D., Hart K. Facilitating dietary change in renal disease: investigating patients' perspectives. J Ren Care 2008, 34:136-142.
18. Paes-Barreto J.G., Barreto Silva M.I., Qureshi A.R., Bregman R., Cervante V.F., Carrero J.J., et al. Can renal nutrition education improve adherence to a low-protein diet in patients with stages 3 to 5 chronic kidney disease?. J Ren Nutr 2012, Available at:, Accessed January 29, 2013. http://www.jrnjournal.org/article/S1051-2276(12)00203-8/abstract.
19. Carrero J.J., Qureshi A.R., Axelsson J., Avesani C.M., Suliman M.E., Kato S., et al. Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr 2007, 85:695-701.
20. Kalantar-Zadeh K., Block G., McAllister C.J., Humphreys M.H., Kopple J.D. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004, 80:299-307.
21. Lopes A.A., Elder S.J., Ginsberg N., Andreucci V.E., Cruz J.M., Fukuhara S., et al. Lack of appetite in haemodialysis patients-associations with patient characteristics, indicators of nutritional status and outcomes in the international DOPPS. Nephrol Dial Transpl 2007, 22:3538-3546.
22. Bossola M., Tazza L., Giungi S., Luciani G. Anorexia in hemodialysis patients: an update. Kidney Int 2006, 70:417-422.
23. Carrero J.J. Identification of patients with eating disorders: clinical and biochemical signs of appetite loss in dialysis patients. J Ren Nutr 2009, 19:10-15.
24. Kopple J.D., Berg R., Houser H., Steinman T.I., Teschan P. Nutritional status of patients with different levels of chronic renal insufficiency. Modification of diet in renal disease (MDRD) study group. Kidney Int Suppl 1989, 27:S184-S194.
25. Duenhas M.R., Draibe S.A., Avesani C.M., Sesso R., Cuppari L. Influence of renal function on spontaneous dietary intake and on nutritional status of chronic renal insufficiency patients. Eur J Clin Nutr 2003, 57:1473-1478.
26. Ikizler T.A., Greene J.H., Wingard R.L., Parker R.A., Hakim R.M. Spontaneous dietary protein intake during progression of chronic renal failure. J Am Soc Nephrol 1995, 6:1386-1391.
27. Carrero J.J. Mechanisms of altered regulation of food intake in chronic kidney disease. J Ren Nutr 2011, 21:7-11.
28. Wright M., Woodrow G., O'Brien S., Armstrong E., King N., Dye L., et al. Cholecystokinin and leptin: their influence upon the eating behaviour and nutrient intake of dialysis patients. Nephrol Dial Transpl 2004, 19:133-140.
29. Perez-Fontan M., Cordido F., Rodriguez-Carmona A., Penin M., Diaz-Cambre H., Lopez-Muniz A., et al. Short-term regulation of peptide YY secretion by a mixed meal or peritoneal glucose-based dialysate in patients with chronic renal failure. Nephrol Dial Transpl 2008, 23:3696-3703.
30. Muscaritoli M., Molfino A., Chiappini M.G., Laviano A., Ammann T., Spinsanti P., et al. Anorexia in hemodialysis patients: the possible role of des-acyl ghrelin. Am J Nephrol 2007, 27:360-365.
31. Carrero J.J., Nakashima A., Qureshi A.R., Lindholm B., Heimburger O., Barany P., et al. Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. Kidney Int 2011, 79:749-756.
32. Cheung W., Yu P.X., Little B.M., Cone R.D., Marks D.L., Mak R.H. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 2005, 115:1659-1665.
33. Carrero J.J., Witasp A., Stenvinkel P., Qureshi A.R., Heimburger O., Barany P., et al. Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. Nephrol Dial Transpl 2010, 25:901-906.
34. Carrero J.J., Stenvinkel P. Nutrition: Can ghrelin improve appetite in uremic wasting?. Nat Rev Nephrol 2009, 5:672-673.
35. Bossola M., Scribano D., Colacicco L., Tavazzi B., Giungi S., Zuppi C., et al. Anorexia and plasma levels of free tryptophan, branched chain amino acids, and ghrelin in hemodialysis patients. J Ren Nutr 2009, 19:248-255.
36. Akar H., Akar G.C., Carrero J.J., Stenvinkel P., Lindholm B. Systemic consequences of poor oral health in chronic kidney disease patients. Clin J Am Soc Nephrol 2011, 6:218-226.
37. Bossola M., Luciani G., Rosa F., Tazza L. Appetite and gastrointestinal symptoms in chronic hemodialysis patients. J Ren Nutr 2011, 21:448-454.
38. Aguilera A., Bajo M.A., Espinoza M., Olveira A., Paiva A.M., Codoceo R., et al. Gastrointestinal and pancreatic function in peritoneal dialysis patients: their relationship with malnutrition and peritoneal membrane abnormalities. Am J Kidney Dis 2003, 42:787-796.
39. Van Vlem B., Schoonjans R., Vanholder R., De Vos M., Vandamme W., Van Laecke S., et al. Delayed gastric emptying in dyspeptic chronic hemodialysis patients. Am J Kidney Dis 2000, 36:962-968.
40. Aguilera A., Gonzalez-Espinoza L., Codoceo R., Jara Mdel C., Pavone M., Bajo M.A., et al. Bowel bacterial overgrowth as another cause of malnutrition, inflammation, and atherosclerosis syndrome in peritoneal dialysis patients. Adv Perit Dial 2010, 26:130-136.
41. Hung K.C., Wu C.C., Chen H.S., Ma W.Y., Tseng C.F., Yang L.K., et al. Serum IL-6, albumin and co-morbidities are closely correlated with symptoms of depression in patients on maintenance haemodialysis. Nephrol Dial Transpl 2011, 26:658-664.
42. Evans W.J., Morley J.E., Argiles J., Bales C., Baracos V., Guttridge D., et al. Cachexia: a new definition. Clin Nutr (Edinburgh, Scotland) 2008, 27:793-799.
43. Morley J.E., Thomas D.R. Cachexia: new advances in the management of wasting diseases. J Am Med Dir Assoc 2008, 9:205-210.
44. Shetty P.S. Adaptation to low energy intakes: the responses and limits to low intakes in infants, children and adults. Eur J Clin Nutr 1999, 53(suppl 1):S14-S33.
45. Emery P.W. Metabolic changes in malnutrition. Eye 2005, 19:1029-1034.
46. Waterlow J.C., Garlick P.J., Millward D.J. Protein turnover in mammalian tissues and in the whole body 1978, North Holland, Amsterdam, The Netherlands.
47. Franch H.A., Mitch W.E. Navigating between the scylla and charybdis of prescribing dietary protein for chronic kidney diseases. Annu Rev Nutr 2009, 29:341-364.
48. Golden M.H. The development of concepts of malnutrition. J Nutr 2002, 132:2117S-2122S.
49. Don B.R., Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial 2004, 17:432-437.
50. Myron Johnson A., Merlini G., Sheldon J., Ichihara K. Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. Clin Chem Lab Med 2007, 45:419-426.
51. Finn P.F., Dice J.F. Proteolytic and lipolytic responses to starvation. Nutrition 2006, 22:830-844.
52. Neyra R., Chen K.Y., Sun M., Shyr Y., Hakim R.M., Ikizler T.A. Increased resting energy expenditure in patients with end-stage renal disease. JPEN J Parenter Enteral Nutr 2003, 27:36-42.
53. Wang A.Y., Sea M.M., Tang N., Sanderson J.E., Lui S.F., Li P.K., et al. Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. J Am Soc Nephrol 2004, 15:3134-3143.
54. Cuppari L., de Carvalho A.B., Avesani C.M., Kamimura M.A., Dos Santos Lobao R.R., Draibe S.A. Increased resting energy expenditure in hemodialysis patients with severe hyperparathyroidism. J Am Soc Nephrol 2004, 15:2933-2939.
55. Avesani C.M., Cuppari L., Silva A.C., Sigulem D.M., Cendoroglo M., Sesso R., et al. Resting energy expenditure in pre-dialysis diabetic patients. Nephrol Dial Transpl 2001, 16:556-565.
56. Utaka S., Avesani C.M., Draibe S.A., Kamimura M.A., Andreoni S., Cuppari L. Inflammation is associated with increased energy expenditure in patients with chronic kidney disease. Am J Clin Nutr 2005, 82:801-805.
57. Kamimura M.A., Draibe S.A., Dalboni M.A., Cendoroglo M., Avesani C.M., Manfredi S.R., et al. Serum and cellular interleukin-6 in haemodialysis patients: relationship with energy expenditure. Nephrol Dial Transpl 2007, 22:839-844.
58. Ikizler T.A., Pupim L.B., Brouillette J.R., Levenhagen D.K., Farmer K., Hakim R.M., et al. Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Am J Physiol Endocrinol Metab 2002, 282:E107-E116.
59. Mafra D., Deleaval P., Teta D., Cleaud C., Arkouche W., Jolivot A., et al. Influence of inflammation on total energy expenditure in hemodialysis patients. J Ren Nutr 2011, 21:387-393.
60. Avesani C.M., Trolonge S., Deleaval P., Baria F., Mafra D., Faxen-Irving G., et al. Physical activity and energy expenditure in haemodialysis patients: an international survey. Nephrol Dial Transpl 2012, 27:2430-2434.
61. Spindler S.R. Caloric restriction: from soup to nuts. Ageing Res Rev 2010, 9:324-353.
62. Kaysen G.A., Greene T., Daugirdas J.T., Kimmel P.L., Schulman G.W., Toto R.D., et al. Longitudinal and cross-sectional effects of C-reactive protein, equilibrated normalized protein catabolic rate, and serum bicarbonate on creatinine and albumin levels in dialysis patients. Am J Kidney Dis 2003, 42:1200-1211.
63. Tomkins A.M., Garlick P.J., Schofield W.N., Waterlow J.C. The combined effects of infection and malnutrition on protein metabolism in children. Clin Sci 1983, 65:313-324.
64. Keusch G.T. The history of nutrition: malnutrition, infection and immunity. J Nutr 2003, 133:336S-340S.
65. Carrero J.J., Stenvinkel P. Inflammation in end-stage renal disease-what have we learned in 10 years?. Semin Dial 2010, 23:498-509.
66. Stenvinkel P., Ketteler M., Johnson R.J., Lindholm B., Pecoits-Filho R., Riella M., et al. IL-10, IL-6, and TNFF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 2005, 67:1216-1233.
67. Carrero J.J., Chmielewski M., Axelsson J., Snaedal S., Heimburger O., Barany P., et al. Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. Clin Nutr (Edinburgh, Scotland) 2008, 27:557-564.
68. Miyamoto T., Rashid Qureshi A., Heimburger O., Barany P., Carrero K., Sjoberg B., et al. Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. Clin J Am Soc Nephrol 2011, 6:2785-2791.
69. Delano M.J., Moldawer L.L. The origins of cachexia in acute and chronic inflammatory diseases. Nutr Clin Pract 2006, 21:68-81.
70. Meuwese C.L., Stenvinkel P., Dekker F.W., Carrero J.J. Monitoring of inflammation in patients on dialysis: forewarned is forearmed. Nat Rev Nephrol 2011, 7:166-176.
71. Carrero J.J., Aguilera A., Stenvinkel P., Gil F., Selgas R., Lindholm B. Appetite disorders in uremia. J Ren Nutr 2008, 18:107-113.
72. Avesani C.M., Carrero J.J., Axelsson J., Qureshi A.R., Lindholm B., Stenvinkel P. Inflammation and wasting in chronic kidney disease: partners in crime. Kidney Int Suppl 2006, 70:S8-S13.
73. Hu Z., Wang H., Lee I.H., Du J., Mitch W.E. Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J Clin Invest 2009, 119:3059-3069.
74. Zhang L., Du J., Hu Z., Han G., Delafontaine P., Garcia G., et al. IL-6 and serum amyloid a synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol 2009, 20:604-612.
75. Raj D.S., Moseley P., Dominic E.A., Onime A., Tzamaloukas A.H., Boyd A., et al. Interleukin-6 modulates hepatic and muscle protein synthesis during hemodialysis. Kidney Int 2008, 73:1054-1061.
76. Boivin M.A., Battah S.I., Dominic E.A., Kalantar-Zadeh K., Ferrando A., Tzamaloukas A.H., et al. Activation of caspase-3 in the skeletal muscle during haemodialysis. Eur J Clin Invest 2010, 40:903-910.
77. Wang X.H., Hu Z., Klein J.D., Zhang L., Fang F., Mitch W.E. Decreased mir-29 suppresses myogenesis in CKD. J Am Soc Nephrol 2011, 22:2068-2076.
78. Zhang L., Rajan V., Lin E., Hu Z., Han H.Q., Zhou X., et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J 2011, 25:1653-1663.
79. Hansen J., Brandt C., Nielsen A.R., Hojman P., Whitham M., Febbraio M.A., et al. Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine. Endocrinology 2011, 152:164-171.
80. Leehey D.J., Moinuddin I., Bast J.P., Qureshi S., Jelinek C.S., Cooper C., et al. Aerobic exercise in obese diabetic patients with chronic kidney disease: a randomized and controlled pilot study. Cardiovasc Diabetol 2009, 8:62.
81. Miyamoto T., Carrero J.J., Qureshi A.R., Anderstam B., Heimburger O., Barany P., et al. Circulating follistatin in patients with chronic kidney disease: implications for muscle strength, bone mineral density, inflammation, and survival. Clin J Am Soc Nephrol 2011, 6:1001-1008.
82. Lazarus D.D., Moldawer L.L., Lowry S.F. Insulin-like growth factor-1 activity is inhibited by interleukin-1 alpha, tumor necrosis factor-alpha, and interleukin-6. Lymphokine Cytokine Res 1993, 12:219-223.
83. Axelsson J., Qureshi A.R., Divino-Filho J.C., Barany P., Heimburger O., Lindholm B., et al. Are insulin-like growth factor and its binding proteins 1 and 3 clinically useful as markers of malnutrition, sarcopenia and inflammation in end-stage renal disease?. Eur J Clin Nutr 2006, 60:718-726.
84. Mak R.H., Rotwein P. Myostatin and insulin-like growth factors in uremic sarcopenia: the yin and yang in muscle mass regulation. Kidney Int 2006, 70:410-412.
85. Carrero J.J., Ortiz A., Qureshi A.R., Martin-Ventura J.L., Barany P., Heimburger O., et al. Additive effects of soluble tweak and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009, 4:110-118.
86. Dogra C., Changotra H., Wedhas N., Qin X., Wergedal J.E., Kumar A. TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J 2007, 21:1857-1869.
87. Sun S.C. The noncanonical NF-kappab pathway. Immunol Rev 2012, 246:125-140.
88. Argiles J.M., Lopez-Soriano F.J., Busquets S. Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity. Drug Discov Today 2009, 14:208-213.
89. Honda H., Qureshi A.R., Axelsson J., Heimburger O., Suliman M.E., Barany P., et al. Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. Am J Clin Nutr 2007, 86:633-638.
90. Carrero J.J., Cordeiro A.C., Lindholm B., Stenvinkel P. The emerging pleiotrophic role of adipokines in the uremic phenotype. Curr Opin Nephrol Hypertens 2010, 19:37-42.
91. Witasp A., Carrero J.J., Heimburger O., Lindholm B., Hammarqvist F., Stenvinkel P., et al. Increased expression of pro-inflammatory genes in abdominal subcutaneous fat in advanced chronic kidney disease patients. J Intern Med 2011, 269:410-419.
92. Carvalho L.K., Barreto Silva M.I., da Silva Vale B., Bregman R., Martucci R.B., Carrero J.J., et al. Annual variation in body fat is associated with systemic inflammation in chronic kidney disease patients stages 3 and 4: a longitudinal study. Nephrol Dial Transpl 2012, 27:1423-1428.
93. Axelsson J., Rashid Qureshi A., Suliman M.E., Honda H., Pecoits-Filho R., Heimburger O., et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004, 80:1222-1229.
94. Gohda T., Gotoh H., Tanimoto M., Sato M., Io H., Kaneko K., et al. Relationship between abdominal fat accumulation and insulin resistance in hemodialysis patients. Hypertens Res 2008, 31:83-88.
95. Odamaki M., Furuya R., Ohkawa S., Yoneyama T., Nishikino M., Hishida A., et al. Altered abdominal fat distribution and its association with the serum lipid profile in non-diabetic haemodialysis patients. Nephrol Dial Transpl 1999, 14:2427-2432.
96. Odamaki M., Furuya R., Kinumura Y., Ikegaya N., Kumagai H. Association between plasma adiponectin concentration and visceral fat accumulation in hemodialysis patients. Nephron Clin Pract 2006, 102:c8-c13.
97. Ramos L.F., Shintani A., Ikizler T.A., Himmelfarb J. Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol 2008, 19:593-599.
98. Witasp A., Carrero J.J., Hammarqvist F., Qureshi A.R., Heimburger O., Schalling M., et al. Expression of osteoprotegerin in human fat tissue; implications for chronic kidney disease. Eur J Clin Invest 2011, 41:498-506.
99. Kamimura M.A., Carrero J.J., Canziani M.E., Watanabe R., Lemos M.M., Cuppari L. Visceral obesity assessed by computed tomography predicts cardiovascular events in chronic kidney disease patients. Nutr Metab Cardiovasc Dis 2012, Available at:, Accessed January 29, 2013. http://www.nmcd-journal.com/article/S0939-4753(12)00155-X/abstract.
100. Postorino M., Marino C., Tripepi G., Zoccali C. Abdominal obesity and all-cause and cardiovascular mortality in end-stage renal disease. J Am Coll Cardiol 2009, 53:1265-1272.
101. Cordeiro A.C., Qureshi A.R., Stenvinkel P., Heimbürger O., Axelsson J., Bárány P., et al. Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. Nephrol Dial Transplant 2010, 25:562-568.
102. Postorino M., Marino C., Tripepi G., Zoccali C. Abdominal obesity modifies the risk of hypertriglyceridemia for all-cause and cardiovascular mortality in hemodialysis patients. Kidney Int 2011, 79:765-772.
103. Zoccali C., Postorino M., Marino C., Pizzini P., Cutrupi S., Tripepi G. Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients. J Intern Med 2011, 269:172-181.
104. Yamamoto T., Carrero J.J., Lindholm B., Stenvinkel P., Axelsson J. Leptin and uremic protein-energy wasting-the axis of eating. Semin Dial 2009, 22:387-390.
105. Bossola M., Muscaritoli M., Valenza V., Panocchia N., Tazza L., Cascino A., et al. Anorexia and serum leptin levels in hemodialysis patients. Nephron Clin Pract 2004, 97:c76-c82.
106. Park S.H., Carrero J.J., Lindholm B., Stenvinkel P. Adiponectin in chronic kidney disease has an opposite impact on protein-energy wasting and cardiovascular risk: two sides of the same coin. Clin Nephrol 2009, 72:87-96.
107. Carrero J.J., Park S.H., Axelsson J., Lindholm B., Stenvinkel P. Cytokines, atherogenesis, and hypercatabolism in chronic kidney disease: a dreadful triad. Semin Dial 2009, 22:381-386.
108. Kistorp C., Faber J., Galatius S., Gustafsson F., Frystyk J., Flyvbjerg A., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005, 112:1756-1762.
109. Drechsler C., Krane V., Winkler K., Dekker F.W., Wanner C. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int 2009, 76:567-575.
110. Qi Y., Takahashi N., Hileman S.M., Patel H.R., Berg A.H., Pajvani U.B., et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004, 10:524-529.
111. Liu S.W., Qiao S.B., Yuan J.S., Liu D.Q. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol 2009, 71:202-207.
112. Yilmaz M.I., Saglam M., Qureshi A.R., Carrero J.J., Caglar K., Eyileten T., et al. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transpl 2008, 23:1621-1627.
113. Hallschmid M., Randeva H., Tan B.K., Kern W., Lehnert H. Relationship between cerebrospinal fluid visfatin (PBEF/NAMPT) levels and adiposity in humans. Diabetes 2009, 58:637-640.
114. Price S.R., Gooch J.L., Donaldson S.K., Roberts-Wilson T.K. Muscle atrophy in chronic kidney disease results from abnormalities in insulin signaling. J Ren Nutr 2010, 20:S24-S28.
115. Flakoll P.J., Carlson M., Cherrington A.C. Physiological action of insulin. Diabetes Mellitus: a Fundamental and Clinical Text 2000, 148-161. Williams & Wilkins, Philadelphia, PA. D.T.S. Leroith, J. Olefsky (Eds.).
116. Runyan J.W., Hurwitz D., Robbins S.L. Effect of Kimmelstiel-Wilson syndrome on insulin requirements in diabetes. N Engl J Med 1955, 252:388-391.
117. DeFronzo R.A., Alvestrand A., Smith D., Hendler R., Hendler E., Wahren J. Insulin resistance in uremia. J Clin Invest 1981, 67:563-568.
118. DeFronzo R.A., Smith D., Alvestrand A. Insulin action in uremia. Kidney Int Suppl 1983, 16:S102-S114.
119. Pupim L.B., Flakoll P.J., Majchrzak K.M., Aftab Guy D.L., Stenvinkel P., Ikizler T.A. Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus. Kidney Int 2005, 68:1857-1865.
120. Siew E.D., Pupim L.B., Majchrzak K.M., Shintani A., Flakoll P.J., Ikizler T.A. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int 2007, 71:146-152.
121. Koppe L., Pillon N.J., Vella R.E., Croze M.L., Pelletier C.C., Chambert S., et al. P-cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol 2013, 24:88-99.
122. Wang X., Hu Z., Hu J., Du J., Mitch W.E. Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 2006, 147:4160-4168.
123. Brunelli S.M., Thadhani R., Ikizler T.A., Feldman H.I. Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. Kidney Int 2009, 75:961-968.
124. Mitch W.E., Du J., Bailey J.L., Price S.R. Mechanisms causing muscle proteolysis in uremia: the influence of insulin and cytokines. Miner Electrolyte Metab 1999, 25:216-219.
125. Ding H., Gao X.L., Hirschberg R., Vadgama J.V., Kopple J.D. Impaired actions of insulin-like growth factor 1 on protein synthesis and degradation in skeletal muscle of rats with chronic renal failure. Evidence for a postreceptor defect. J Clin Invest 1996, 97:1064-1075.
126. Zheng B., Ohkawa S., Li H., Roberts-Wilson T.K., Price S.R. Foxo3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/mafbx expression during glucocorticoid-induced skeletal muscle atrophy. FASEB J 2010, 24:2660-2669.
127. Du J., Wang X., Miereles C., Bailey J.L., Debigare R., Zheng B., et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 2004, 113:115-123.
128. Carrero J.J., Kyriazis J., Sonmez A., Tzanakis I., Qureshi A.R., Stenvinkel P., et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol 2012, 7:207-215.
129. Carrero J.J., Qureshi A.R., Nakashima A., Arver S., Parini P., Lindholm B., et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transpl 2011, 26:184-190.
130. Gungor O., Kircelli F., Carrero J.J., Asci G., Toz H., Tatar E., et al. Endogenous testosterone and mortality in male hemodialysis patients: is it the result of aging?. Clin J Am Soc Nephrol 2010, 5:2018-2023.
131. Yilmaz M.I., Sonmez A., Qureshi A.R., Saglam M., Stenvinkel P., Yaman H., et al. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin J Am Soc Nephrol 2011, 6:1617-1625.
132. Carrero J.J., Barany P., Yilmaz M.I., Qureshi A.R., Sonmez A., Heimburger O., et al. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Nephrol Dial Transpl 2012, 27:709-715.
133. Carrero J.J., Stenvinkel P. The vulnerable man: impact of testosterone deficiency on the uraemic phenotype. Nephrol Dial Transpl 2012, 27:4030-4041.
134. Carrero J.J., Qureshi A.R., Parini P., Arver S., Lindholm B., Barany P., et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 2009, 20:613-620.
135. Kyriazis J., Tzanakis I., Stylianou K., Katsipi I., Moisiadis D., Papadaki A., et al. Low serum testosterone, arterial stiffness and mortality in male haemodialysis patients. Nephrol Dial Transpl 2011, 26:2971-2977.
136. Haring R., Nauck M., Volzke H., Endlich K., Lendeckel U., Friedrich N., et al. Low serum testosterone is associated with increased mortality in men with stage 3 or greater nephropathy. Am J Nephrol 2011, 33:209-217.
137. Cigarran S., Pousa M., Castro M.J., Gonzalez B., Martinez A., Barril G., et al. Endogenous testosterone, muscle strength, and fat-free mass in men with chronic kidney disease. J Ren Nutr 2012, pii:S1051-2276.
138. Johansen K.L., Mulligan K., Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999, 281:1275-1281.
139. Johansen K.L., Painter P.L., Sakkas G.K., Gordon P., Doyle J., Shubert T. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: a randomized, controlled trial. J Am Soc Nephrol 2006, 17:2307-2314.
140. Vanhorebeek I., Langouche L., Van den Berghe G. Endocrine aspects of acute and prolonged critical illness. Nat Clin Pract 2006, 2:20-31.
141. Carrero J.J., Qureshi A.R., Axelsson J., Yilmaz M.I., Rehnmark S., Witt M.R., et al. Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. J Intern Med 2007, 262:690-701.
142. Zoccali C., Mallamaci F., Tripepi G., Cutrupi S., Pizzini P. Low triiodothyronine and survival in end-stage renal disease. Kidney Int 2006, 70:523-528.
143. Yilmaz M.I., Sonmez A., Karaman M., Ay S.A., Saglam M., Yaman H., et al. Low triiodothyronine alters flow-mediated vasodilatation in advanced nondiabetic kidney disease. Am J Nephrol 2011, 33:25-32.
144. Meuwese C.L., Dekker F.W., Lindholm B., Qureshi A.R., Heimburger O., Barany P., et al. Baseline levels and trimestral variation of triiodothyronine and thyroxine and their association with mortality in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2012, 7:131-138.
145. Wiederkehr M.R., Kalogiros J., Krapf R. Correction of metabolic acidosis improves thyroid and growth hormone axes in haemodialysis patients. Nephrol Dial Transpl 2004, 19:1190-1197.
146. Disthabanchong S., Treeruttanawanich A. Oral sodium bicarbonate improves thyroid function in predialysis chronic kidney disease. Am J Nephrol 2010, 32:549-556.
147. Ozen K.P., Asci G., Gungor O., Carrero J.J., Kircelli F., Tatar E., et al. Nutritional state alters the association between free triiodothyronine levels and mortality in hemodialysis patients. Am J Nephrol 2011, 33:305-312.
148. Bailey J.L., England B.K., Long R.C., Weissman J., Mitch W.E. Experimental acidemia and muscle cell ph in chronic acidosis and renal failure. Am J Physiol 1995, 269:C706-C712.
149. Franch H.A., Raissi S., Wang X., Zheng B., Bailey J.L., Price S.R. Acidosis impairs insulin receptor substrate-1-associated phosphoinositide 3-kinase signaling in muscle cells: consequences on proteolysis. Am J Physiol Ren Physiol 2004, 287:F700-F706.
150. Lee S.W., Dai G., Hu Z., Wang X., Du J., Mitch W.E. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol 2004, 15:1537-1545.
151. May R.C., Kelly R.A., Mitch W.E. Metabolic acidosis stimulates protein degradation in rat muscle by a glucocorticoid-dependent mechanism. J Clin Invest 1986, 77:614-621.
152. Song Y.H., Li Y., Du J., Mitch W.E., Rosenthal N., Delafontaine P. Muscle-specific expression of igf-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 2005, 115:451-458.
153. Lecker S.H., Jagoe R.T., Gilbert A., Gomes M., Baracos V., Bailey J., et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004, 18:39-51.
154. Kalhoff H., Diekmann L., Kunz C., Stock G.J., Manz F. Alkali therapy versus sodium chloride supplement in low birthweight infants with incipient late metabolic acidosis. Acta Paediatr 1997, 86:96-101.
155. McSherry E., Morris R.C. Attainment and maintenance of normal stature with alkali therapy in infants and children with classic renal tubular acidosis. J Clin Invest 1978, 61:509-527.
156. Frassetto L., Morris R.C., Sebastian A. Potassium bicarbonate reduces urinary nitrogen excretion in postmenopausal women. J Clin Endocrinol Metab 1997, 82:254-259.
157. Ballmer P.E., McNurlan M.A., Hulter H.N., Anderson S.E., Garlick P.J., Krapf R. Chronic metabolic acidosis decreases albumin synthesis and induces negative nitrogen balance in humans. J Clin Invest 1995, 95:39-45.
158. Reaich D., Channon S.M., Scrimgeour C.M., Goodship T.H. Ammonium chloride-induced acidosis increases protein breakdown and amino acid oxidation in humans. Am J Physiol 1992, 263:E735-E739.
159. Reaich D., Channon S.M., Scrimgeour C.M., Daley S.E., Wilkinson R., Goodship T.H. Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation. Am J Physiol 1993, 265:E230-E235.
160. Graham K.A., Reaich D., Channon S.M., Downie S., Goodship T.H. Correction of acidosis in hemodialysis decreases whole-body protein degradation. J Am Soc Nephrol 1997, 8:632-637.
161. Graham K.A., Reaich D., Channon S.M., Downie S., Gilmour E., Passlick-Deetjen J., et al. Correction of acidosis in CAPD decreases whole body protein degradation. Kidney Int 1996, 49:1396-1400.
162. Stein A., Moorhouse J., Iles-Smith H., Baker F., Johnstone J., James G., et al. Role of an improvement in acid-base status and nutrition in CAPD patients. Kidney Int 1997, 52:1089-1095.
163. de Brito-Ashurst I., Varagunam M., Raftery M.J., Yaqoob M.M. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009, 20:2075-2084.
164. Pupim L.B., Heimburger O., Qureshi A.R., Ikizler T.A., Stenvinkel P. Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. Kidney Int 2005, 68:2368-2374.
165. Kalantar-Zadeh K., Derose S.F., Nicholas S., Benner D., Sharma K., Kovesdy C.P. Burnt-out diabetes: impact of chronic kidney disease progression on the natural course of diabetes mellitus. J Ren Nutr 2009, 19:33-37.
166. von Haehling S., Lainscak M., Springer J., Anker S.D. Cardiac cachexia: a systematic overview. Pharmacol Ther 2009, 121:227-252.
167. Wang A.Y., Sea M.M., Tang N., Lam C.W., Chan I.H., Lui S.F., et al. Energy intake and expenditure profile in chronic peritoneal dialysis patients complicated with circulatory congestion. Am J Clin Nutr 2009, 90:1179-1184.
168. Cuppari L., Garcia-Lopes M.G. Hypovitaminosis D in chronic kidney disease patients: prevalence and treatment. J Ren Nutr 2009, 19:38-43.
169. Garcia L.A., King K.K., Ferrini M.G., Norris K.C., Artaza J.N. 1,25(OH)2vitamin D3 stimulates myogenic differentiation by inhibiting cell proliferation and modulating the expression of promyogenic growth factors and myostatin in C2C12 skeletal muscle cells. Endocrinology 2011, 152:2976-2986.
170. Harter H.R., Birge S.J., Martin K.J., Klahr S., Karl I.E. Effects of vitamin D metabolites on protein catabolism of muscle from uremic rats. Kidney Int 1983, 23:465-472.
171. Gordon P.L., Sakkas G.K., Doyle J.W., Shubert T., Johansen K.L. Relationship between vitamin d and muscle size and strength in patients on hemodialysis. J Ren Nutr 2007, 17:397-407.
172. Lee D.M., Tajar A., Pye S.R., Boonen S., Vanderschueren D., Bouillon R., et al. Association of hypogonadism with vitamin D status: the European male ageing study. Eur J Endocrinol 2012, 166:77-85.
173. Kimmel P.L., Peterson R.A., Weihs K.L., Simmens S.J., Alleyne S., Cruz I., et al. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int 2000, 57:2093-2098.
174. Riezebos R.K., Nauta K.J., Honig A., Dekker F.W., Siegert C.E. The association of depressive symptoms with survival in a Dutch cohort of patients with end-stage renal disease. Nephrol Dial Transpl 2010, 25:231-236.
175. Chilcot J., Wellsted D., Vilar E., Farrington K. An association between residual renal function and depression symptoms in haemodialysis patients. Nephron Clin Pract 2009, 113:c117-c124.
176. Schiepers O.J., Wichers M.C., Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:201-217.
177. Sonikian M., Metaxaki P., Papavasileiou D., Boufidou F., Nikolaou C., Vlassopoulos D., et al. Effects of interleukin-6 on depression risk in dialysis patients. Am J Nephrol 2010, 31:303-308.
178. Montinaro V., Iaffaldano G.P., Granata S., Porcelli P., Todarello O., Schena F.P., et al. Emotional symptoms, quality of life and cytokine profile in hemodialysis patients. Clin Nephrol 2010, 73:36-43.
179. Lee S.K., Lee H.S., Lee T.B., Kim D.H., Koo J.R., Kim Y.K., et al. The effects of antidepressant treatment on serum cytokines and nutritional status in hemodialysis patients. J Korean Med Sci 2004, 19:384-389.
180. Jhamb M., Argyropoulos C., Steel J.L., Plantinga L., Wu A.W., Fink N.E., et al. Correlates and outcomes of fatigue among incident dialysis patients. Clin J Am Soc Nephrol 2009, 4:1779-1786.
181. Johansen K.L., Painter P. Exercise in individuals with CKD. Am J Kidney Dis 2012, 59:126-134.
182. Ferrucci L., Penninx B.W., Volpato S., Harris T.B., Bandeen-Roche K., Balfour J., et al. Change in muscle strength explains accelerated decline of physical function in older women with high interleukin-6 serum levels. J Am Geriatr Soc 2002, 50:1947-1954.
183. Johansen K.L., Chertow G.M., Jin C., Kutner N.G. Significance of frailty among dialysis patients. J Am Soc Nephrol 2007, 18:2960-2967.
184. LeBrasseur N.K., Walsh K., Arany Z. Metabolic benefits of resistance training and fast glycolytic skeletal muscle. Am J Physiol 2011, 300:E3-E10.
185. Workeneh B.T., Rondon-Berrios H., Zhang L., Hu Z., Ayehu G., Ferrando A., et al. Development of a diagnostic method for detecting increased muscle protein degradation in patients with catabolic conditions. J Am Soc Nephrol 2006, 17:3233-3239.
186. Rao M., Li L., Demello C., Guo D., Jaber B.L., Pereira B.J., et al. Mitochondrial DNA injury and mortality in hemodialysis patients. J Am Soc Nephrol 2009, 20:189-196.
187. Dolinsky V.W., Jones K.E., Sidhu R.S., Haykowsky M., Czubryt M.P., Gordon T., et al. Improvements in skeletal muscle strength and cardiac function induced by resveratrol contribute to enhanced exercise performance in rats. J Physiol 2012, 590:2783-2799.
188. Heiwe S., Jacobson S.H. Exercise training for adults with chronic kidney disease. Cochrane Database Syst Rev 2011, CD003236.
189. Lofberg E., Essen P., McNurlan M., Wernerman J., Garlick P., Anderstam B., et al. Effect of hemodialysis on protein synthesis. Clin Nephrol 2000, 54:284-294.
190. Mokrzycki M.H., Kaplan A.A. Protein losses in continuous renal replacement therapies. J Am Soc Nephrol 1996, 7:2259-2263.
191. Davies S.P., Reaveley D.A., Brown E.A., Kox W.J. Amino acid clearances and daily losses in patients with acute renal failure treated by continuous arteriovenous hemodialysis. Crit Care Med 1991, 19:1510-1515.
192. Schepky A.G., Bensch K.W., Schulz-Knappe P., Forssmann W.G. Human hemofiltrate as a source of circulating bioactive peptides: determination of amino acids, peptides and proteins. Biomed Chromatogr 1994, 8:90-94.
193. Borah M., Schoenfeld P., Gotch F., Sargent J., Wolfsen M., Humphreys M. Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int 1978, 14:491-500.
194. Lim V.S., Ikizler T.A., Raj D.S., Flanigan M.J. Does hemodialysis increase protein breakdown? Dissociation between whole-body amino acid turnover and regional muscle kinetics. J Am Soc Nephrol 2005, 16:862-868.
195. Raj D.S., Zager P., Shah V.O., Dominic E.A., Adeniyi O., Blandon P., et al. Protein turnover and amino acid transport kinetics in end-stage renal disease. Am J Physiol 2004, 286:E136-E143.
196. Kobayashi H., Borsheim E., Anthony T.G., Traber D.L., Badalamenti J., Kimball S.R., et al. Reduced amino acid availability inhibits muscle protein synthesis and decreases activity of initiation factor eIF2B. Am J Physiol 2003, 284:E488-E498.
197. Caglar K., Peng Y., Pupim L.B., Flakoll P.J., Levenhagen D., Hakim R.M., et al. Inflammatory signals associated with hemodialysis. Kidney Int 2002, 62:1408-1416.
198. Ikizler T.A., Flakoll P.J., Parker R.A., Hakim R.M. Amino acid and albumin losses during hemodialysis. Kidney Int 1994, 46:830-837.
199. Pupim L.B., Majchrzak K.M., Flakoll P.J., Ikizler T.A. Intradialytic oral nutrition improves protein homeostasis in chronic hemodialysis patients with deranged nutritional status. J Am Soc Nephrol 2006, 17:3149-3157.
200. Veeneman J.M., Kingma H.A., Boer T.S., Stellaard F., De Jong P.E., Reijngoud D.J., et al. Protein intake during hemodialysis maintains a positive whole body protein balance in chronic hemodialysis patients. Am J Physiol 2003, 284:E954-E965.
201. Tjiong H.L., van den Berg J.W., Wattimena J.L., Rietveld T., van Dijk L.J., van der Wiel A.M., et al. Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. J Am Soc Nephrol 2005, 16:1486-1493.
202. Wang A.Y., Woo J., Wang M., Sea M.M., Sanderson J.E., Lui S.F., et al. Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function. Nephrol Dial Transpl 2005, 20:396-403.
203. Wang A.Y., Sea M.M., Ip R., Law M.C., Chow K.M., Lui S.F., et al. Independent effects of residual renal function and dialysis adequacy on actual dietary protein, calorie, and other nutrient intake in patients on continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 2001, 12:2450-2457.
204. Wang A.Y., Sea M.M., Ip R., Law M.C., Chow K.M., Lui S.F., et al. Independent effects of residual renal function and dialysis adequacy on dietary micronutrient intakes in patients receiving continuous ambulatory peritoneal dialysis. Am J Clin Nutr 2002, 76:569-576.
205. Wang A.Y., Sanderson J., Sea M.M., Wang M., Lam C.W., Li P.K., et al. Important factors other than dialysis adequacy associated with inadequate dietary protein and energy intakes in patients receiving maintenance peritoneal dialysis. Am J Clin Nutr 2003, 77:834-841.